Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00259-015-3254-8PMID 26596724PMCID PMC4814317
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer

  2015cited by this paper
• Radioimmunotherapy of human tumours

  2015cited by this paper
• Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex

  2014cited by this paper
• Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

  2013cited by this paper
• A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.

  2013cited by this paper
• Aumento della captazione del radioiodio indotto da selumetinib in pazienti con cancro della tiroide

  2013cited by this paper
• Practical theoretic guidance for the design of tumor-targeting agents.

  2012cited by this paper
• Pretargeted Molecular Imaging and Radioimmunotherapy

  2012cited by this paper
• Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody

  2012cited by this paper
• Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging

  2012cited by this paper
• Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy

  2011cited by this paper
• ORIGINAL ARTICLE Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system

  2011cited by this paper
• 124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET

  2011cited by this paper
• 124I-huA33 Antibody PET of Colorectal Cancer

  2011cited by this paper
• Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system

  2011cited by this paper
• Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.

  2011cited by this paper
• Use of normal tissue complication probability models in the clinic.

  2010cited by this paper
• A modular IgG-scFv bispecific antibody topology.

  2010cited by this paper
• A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

  2009cited by this paper
• A semiempirical model of tumor pretargeting.

  2008cited by this paper
• Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas.

  2007cited by this paper
• PET Imaging of Soluble Yttrium-86-Labeled Carbon Nanotubes in Mice

  2007cited by this paper
• Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software.

  2007cited by this paper
• Irreversibly binding anti-metal chelate antibodies: Artificial receptors for pretargeting.

  2006cited by this paper
• Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays.

  2003cited by this paper
• Higher Dose and Dose-Rate in Smaller Tumors Result in Improved Tumor Control

  2003cited by this paper
• Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.

  2002cited by this paper
• Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft.

  2001cited by this paper
• Antibodies with infinite affinity

  2001cited by this paper
• A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

  2000cited by this paper
• Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam.

  2000cited by this paper
• Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions.

  2000cited by this paper
• Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging.

  1999cited by this paper
• External Beam Radiotherapy: Comparative Effectiveness in a HumanTumorXenograft

  1999cited by this paper
• New Anti-Cu-TETA and Anti-Y-DOTA Monoclonal Antibodies for Potential Use in the Pre-Targeted Delivery of Radiopharmaceuticals to Tumor

  1998cited by this paper
• Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).

  1996cited by this paper
• Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy.

  1996cited by this paper
• Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.

  1995cited by this paper
• Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.

  1995cited by this paper
• Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.

  1994cited by this paper
• Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.

  1994cited by this paper
• Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.

  1994cited by this paper
• Tumor size: effect on monoclonal antibody uptake in tumor models.

  1986cited by this paper
• Antibodies against metal chelates

  1985cited by this paper

• Preclinical 203/212Pb-DOTA-Based Pretargeted Radioimmunotherapy in Nude Mice Bearing Established Human Colorectal Cancer Xenografts.

  2026cites this paper
• GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer

  2025influential citation
• Comparison of targeting two antigens (GPA33 versus HER2) for 225Ac-pretargeted alpha-radioimmunotherapy of colorectal cancer

  2025cites this paper
• Emerging paradigms in bioorthogonal chemistry for future therapeutics.

  2025cites this paper
• Pretargeted nuclear imaging and radioimmunotherapy based on the inverse electron-demand Diels-Alder reaction.

  2025cites this paper
• Targeted Radionuclide Therapy in Glioblastoma.

  2024cites this paper
• Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten

  2024cites this paper
• Clearing and Masking Agents in Pretargeting Strategies

  2023cites this paper
• Efficacy of HER2-Targeted Intraperitoneal 225Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis

  2023cites this paper
• Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors

  2023cites this paper
• Pretargeting: A Path Forward for Radioimmunotherapy

  2022cites this paper
• A rotaxane-based platform for tailoring the pharmacokinetics of cancer-targeted radiotracers

  2022cites this paper
• Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications.

  2021cites this paper
• Pretargeted Theranostics

  2021cites this paper
• Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis

  2021cites this paper
• Current Pharmaceutical Biotechnology

  2021cites this paper
• Antibody fragment and targeted colorectal cancer therapy: A global systematic review.

  2021cites this paper
• Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma

  2021cites this paper
• Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses

  2020cites this paper
• Application of molecular imaging technology in tumor immunotherapy.

  2020cites this paper
• Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue.

  2020cites this paper
• ImmunoPET: Concept, Design, and Applications.

  2020cites this paper
• Development and clinical application of bispecific antibody in the treatment of colorectal cancer

  2020cites this paper
• Review: PET imaging with macro- and middle-sized molecular probes.

  2020cites this paper
• A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy

  2020cites this paper
• Recent developments in antibody derivatives against colorectal cancer; A review.

  2020cites this paper
• Therapeutic Antibodies and Immunologic Conjugates

  2020cites this paper
• Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction.

  2019cites this paper
• Personalized dosimetry protocol for the optimization of lutetium-177 DOTATATE radionuclide therapy

  2019cites this paper
• Therapeutic Applications of Pretargeting

  2019cites this paper
• A N-acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic Index DOTA-Hapten Pretargeted Radioimmunotherapy.

  2019cites this paper
• A Revisit to the Pretargeting Concept—A Target Conversion

  2018influential citation
• Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma

  2018cites this paper
• Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers

  2018cites this paper
• Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges

  2018cites this paper
• Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection.

  2018cites this paper
• Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers.

  2018cites this paper
• Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer

  2017cites this paper
• Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer

  2017cites this paper
• The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y

  2017cites this paper
• Cancer Biology of Molecular Imaging

  2016cites this paper
• Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies

  2016cites this paper